|
|
News Breaks | | | | January 28, 2013 | | 05:55 EDT |  | BSX, BSX, X, X, TYC, TYC, TROW, TROW, PFE, PFE, PNR, PNR, BTU, BTU, NUE, NUE, NEE, NEE, IP, IP, ITW, ITW, HRS, HRS, HOG, HOG, F, F, EMC, EMC, LLY, LLY, DHR, DHR, GLW, GLW, VLO, VLO | Companies reporting Before the Market Open on Tuesday, January 29
Notable companies reporting before the opening bell on Tuesday include Boston Scientific (BSX), Corning (GLW), D.R. Horton (DHR), Danaher (DHR), Eli Lilly (LLY), EMC (EMC), Ford (F), Harley-Davidson (HOG), Harris (HRS), Illinois Tool Works (ITW), International Paper (IP), NextEra Energy (NEE), Nucor (NUE), Peabody Energy (BTU), Pentair (PNR), Pfizer (PFE), T. Rowe Price Group (TROW), Tyco International (TYC), United States Steel (X), and Valero Energy (VLO). | |
|
News For BSX;GLW;DHR;LLY;EMC;F;HOG;HRS;ITW;IP;NEE;NUE;BTU;PNR;PFE;TROW;TYC;X;VLO From The Last 14 Days Check below for free stories on BSX;GLW;DHR;LLY;EMC;F;HOG;HRS;ITW;IP;NEE;NUE;BTU;PNR;PFE;TROW;TYC;X;VLO the last two weeks. |
|
|
| June 19, 2013 | | 07:54 EDT |  | BTU | Peabody Energy downgraded to Accumulate from Buy at Tudor Pickering
 Subscribe for More Information | | | 07:42 EDT |  | GLW | Corning Q3 earnings to be positive, says Oppenheimer
Subscribe for More Information | | | 07:41 EDT | | PFE | Pfizer holders should consider Zoetis exchange, says BMO Capital
BMO Capital thinks Pfizer (PFE) investors should consider participating in the Zoetis (ZTS) exchange as they have the opportunity to own Zoetis at around $29.40-$29.70 per share, which is 15% below BMO's valuation of $34 per share. Further, BMO thinks there is strong support for Zoetis below $30, which the firm feels lowers downside risk. BMO recommends that Pfizer investors tender around 20% of their shares into the exchange, noting that with the offer likely being oversubscribed, not all tendered shares will be converted to Zoetis. | | | June 18, 2013 | | 11:48 EDT |  | BTU | Stocks with call strike movement; NFLX BTU
Subscribe for More Information | | | 10:54 EDT |  | F | European auto sales decline to 20 year low, Reuters says
European car sales decreased in May to their lowest level for the month in 20 years, says Reuters. Data from the Association of European Carmakers showed Germany, France and Italy, suffered almost double-digit percentage declines in May, Reuters added. Reference Link | | | 10:17 EDT | | LLY | Lilly puts active on FDA says investigating two deaths after Zyprexa injections
Subscribe for More Information | | | 10:12 EDT |  | LLY | FDA investigating two deaths of patients taking Lilly's Zyprexa
The FDA said in a safety announcement on its website that it is investigating two unexplained deaths in patients who received an intramuscular injection of the antipsychotic drug Zyprexa. The patients died 3-4 days after receiving an appropriate dose of the drug, well after the 3-hour post-injection monitoring period required under the Zyprexa Risk Evaluation and Mitigation Strategy, the agency said. Both patients were found to have very high olanzapine blood levels after death. Eli Lilly is the maker of Zyprexa. | | | 09:38 EDT | | PFE | Active equity option families trading on open
Active equity option families trading on open according to Track Data: AAPL NFLX GOOG PFE TSLA MGM | | | 09:08 EDT | | HOG | Harley-Davidson volatility flat into 110th Anniversary Events
Subscribe for More Information | | | 07:40 EDT | | GLW | Corning, view announce strategic collaboration to advance dynamic glass technology
Corning and View announced a strategic development agreement to leverage their combined capabilities to advance View's market-leading dynamic glass. Corning is leading a financial investment in View as part of a Series E round of funding to support the development of dynamic glass technologies for exterior architectural applications. | | | | 05:23 EDT | | BSX | Boston Scientific Vercise DBS System demonstrates improvement in motor function
Patients with Parkinson's disease using the Boston Scientific Vercise DBS, or deep brain stimulation, System showed a significant improvement in motor scores according to interim data from the VANTAGE DBS study. The Vercise DBS System incorporates multiple independent current control, which is designed to selectively stimulate targeted areas in the brain, providing physicians with fine control of stimulation. Preliminary analysis of the VANTAGE study displays approximately 60% mean improvement in motor function at six months post implant, as assessed by UPDRS III when compared to baseline. | | | June 17, 2013 | | 17:14 EDT | | TYC | Tyco settlement with SEC approved by judge, Bloomberg says
Tyco's $13.1M settlement with the SEC over concealed payments to foreign officials was approved by a U.S. District Court judge, reports Bloomberg. Reference Link | | | 17:04 EDT | | BSX | Boston Scientific begins patient enrollment in U.S. clinical trial for Vercise
Subscribe for More Information | | | 16:15 EDT | | TYC | Tyco $13.1M settlement with SEC approved by federal judge, Bloomberg says
| | | 16:00 EDT | | PFE | Options Update; June 17, 2013
Subscribe for More Information | | | 15:53 EDT | | X | S&P downgrades United States Steel to 'BB-'; outlook stable
Subscribe for More Information | | | 11:34 EDT | | LLY | Eli Lilly: LIVALO 4mg has neutral effects on fasting serum glucose levels
Kowa Pharmaceuticals America and Eli Lilly and Company announced results of a pre-specified safety analysis from the INTREPID (HIV-infected patieNts and TREatment with PItavastatin vs. pravastatin for Dyslipidemia) trial evaluating the effect of LIVALO 4 mg compared with pravastatin 40 mg on changes in levels of blood glucose and glycated hemoglobin in HIV-infected adults with dyslipidemia. INTREPID was a Phase 4, multicenter, 12-week randomized superiority study followed by a 40-week safety extension study comparing the lipid-lowering effects of pitavastatin 4 mg and pravastatin 40 mg in adults with HIV infection and dyslipidemia. The results of this pre-specified safety analysis, presented yesterday at the Endocrine Society's 95th Annual Meeting & Expo in San Francisco, CA, showed neutral effects of pitavastatin 4 mg and pravastatin 40 mg on fasting serum glucose and HbA1c levels over 12 weeks. | | | 11:17 EDT |  | LLY | Eli Lilly to host conference call
Subscribe for More Information | | | 08:36 EDT | | PFE | InSite Vision to join Merck, Pfizer patent suit against Mylan
InSite Vision (INSV) announced that it will join Merck (MRK) and Pfizer (PFE) in filing a patent infringement lawsuit against Mylan Pharmaceuticals (MYL). Mylan recently filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration seeking to market a generic version of AzaSite before expiration of the patents covering AzaSite and its use. AzaSite is marketed by Merck in the U.S. On May 26, 2011, InSite and Merck filed a similar patent infringement lawsuit against Sandoz. A trial date for the Sandoz ANDA suit has been set for July 11, 2013. The companies have agreed that Merck will take the lead in prosecuting both lawsuits. Each company will be responsible for their own legal costs, with InSite assuming a monitoring role, the company said. | | | 08:27 EDT | | NEE | U.S. Regulated Utilities sector downgraded at Morgan Stanley
Subscribe for More Information | | |
|
|
|
|
|
|
